Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.